Revance Therapeutics, Inc., a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced the pricing of initial public offering of 6 million shares at $16 per share, before underwriting discounts and commissions. The offering is expected to close on February 11, 2014.
In the amended filing with the SEC, the company had expected to price the initial public offering of 5 million common shares of between $14.00 and $16.00 per share.
The Newark, California-based company shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "RVNC" on February 6, 2014.
Revance, which was founded in 1999, has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments, if any.
Cowen and Company and Piper Jaffray are acting as joint book-running managers for the offering.
by RTT Staff Writer
For comments and feedback: email@example.com